The Federal CM Cap Just Went Up 10x. Arizona Still Hasn't Applied for Medicaid Coverage.

In January 2025, the federal government quietly raised the maximum annual contingency management incentive from $75 to $750 per patient — a tenfold increase that removed the single biggest barrier to operating CM programs at scale. The change got less coverage than it deserved because it arrived without a press release. APA Monitor flagged it in April 2026 alongside the broader picture: more than 100 studies over decades support CM for stimulant use disorders, a 2020 review found long-term benefits for methamphetamine use disorder specifically, and VA data shows a 41% lower mortality rate among VA patients who received CM versus those who did not.

There is one evidence-based behavioral treatment for methamphetamine use disorder, it reduces mortality by 41% in the available data, the federal incentive cap just increased 10x, five states have Medicaid coverage — and Arizona, where methamphetamine use disorder is a leading driver of overdose deaths, has not applied.

Contingency management works by providing small, tangible rewards for drug-negative urine screens — typically gift cards in the $10-$25 range per negative test, accumulating to the annual cap. The mechanism is not mysterious: stimulant use disorders damage the dopamine reward system, reducing the brain’s ability to generate motivation from everyday activities. An external, immediate, reliable reward provides a dopamine signal when the internal signal is turned down. Over time, the internal signal comes back. The evidence is 100+ randomized controlled trials and it is consistent.

California’s Recovery Incentives Program — the most mature Medicaid-covered CM program in the country — reports that approximately 75% of urine samples submitted by participants tested negative for stimulants. The program has enrolled thousands and is expanding to additional counties. California ran this through a Medicaid Section 1115 waiver. Delaware, Hawaii, Montana, and Washington followed. The pathway is established and documented.

The HHS/ASPE guidance on CM implementation describes the CMS waiver process for states and includes model program frameworks. Arizona’s AHCCCS has the mechanism to apply. Arizona has $1.215 billion in opioid settlement funds, some of which are explicitly allocated to evidence-based SUD treatment. Arizona also has a meth overdose problem that is getting worse, not better, in the same years that California’s CM program has been running.

The 10x cap increase removes the argument that CM programs can’t make incentives meaningful without a disproportionate cost. $750 per patient per year is approximately the cost of one emergency room visit averted, one fewer incarceration, one sustained quarter of employment. The math has never been hard. The question is whether the political will follows the evidence.

For Arizona providers and case managers: CM programs can be implemented now without a CMS waiver at the individual clinic level, using philanthropic or grant funding. The state-level Medicaid application would broaden access dramatically. If your organization has the ability to advocate to AHCCCS, the moment — after the federal cap increase, with five state models to point to — is better than it has been.